Global Industry Overview - Biotech
Drug developers are capitalizing on the momentum within the biotechnology industry, driven by optimism fueled by corporate takeovers and a favorable market climate. Kyverna Therapeutics Inc. and Metagenomi Inc. are poised to be the fourth and fifth biotech companies to go public in 2024, following the success of three initial public offerings (IPOs) that collectively raised $786 million, marking the sector's strongest start since 2021.
The first three biotech IPOs of 2024 have demonstrated substantial gains, with ArriVent Biopharma Inc., Alto Neuroscience Inc., and CG Oncology Inc. experiencing share price increases ranging from 22% to 100% above their IPO prices. CG Oncology's significant rally, raising over $10 million, serves as an indication of investors' willingness to support companies with more advanced drug development stages.
A biotech exchange-traded fund has surged by 38% since October, propelled by major pharmaceutical companies like Novartis AG and Bristol Myers Squibb Co. engaging in significant takeovers. Industry experts anticipate a rise in venture capital-backed biotech IPOs, with a specific focus on later-stage companies and drugs presenting near-term catalyst opportunitie
Most Read
Other News
Tbilisi City Hall to launch free lung cancer screening programme from May 1
29.04.2026.16:53
“Tbilisi City Hall is to begin funding a lung cancer screening programme from May 1,” Mayor Kakha Kaladze announced today at a session of the Tbilisi Municipal Government.
According to the Mayor of Tbilisi, free screening will be available to active smokers aged 45 to 75 who are registered in the capital, as well as to those who have quit smoking within the past fifteen years.
“We have helped countless families and individuals through the projects of our City Health and Social Services Agency. Tbilisi City Hall is now taking the next step by funding a lung cancer screening programme. From May 1, the procedure will be entirely free of charge for eligible residents and will be financed by the City Health and Social Services Agency under its Disease Screening Programme. Active smokers aged between 45 and 75 who are registered in the capital, as well as those who quit within the last fifteen years, will be entitled to a free lung cancer screening,” said Kakha Kaladze.
He added that the parameters of the screening programme, including the eligible age range, were determined in close consultation with leading specialists in oncology, radiology and pulmonology. Participating clinics and expert practitioners were selected based on their experience and qualifications.
“The screening will involve a low-dose computed tomography scan, which will be read independently by two radiologists. In the event of differing assessments, a case conference will be convened with the involvement of a third radiologist. Tbilisi City Hall has selected leading clinics that meet the required standards in terms of specialist expertise and technical infrastructure to deliver the programme. At this stage, sixteen medical institutions located across different parts of the capital will be participating in the programme,” the Mayor stated.
Kaladze also noted that lung cancer ranks first in the world for cancer-related mortality, and that screening of high-risk individuals aids in early detection and can increase survival rates by as much as seventy per cent.
